Kennedy Capital Management
ATRA icon

Kennedy Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Kennedy Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,552
Closed -$503K – 667
2020
Q3 		$503K Buy
+1,552
New +$529K 0.01% 590

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Kennedy Capital Management's ATRA Position: Q4 2020 in Review

Kennedy Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 1,552 shares — an estimated $503K sold.

Kennedy Capital Management first reported a position in ATRA in Q3 2020 and held it in 1 quarter. The position peaked at $503K in Q3 2020. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

  • Kennedy Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Kennedy Capital Management sold 1,552 Atara Biotherapeutics shares in Q4 2020, an estimated $503K.
  • Kennedy Capital Management first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 1 quarter.
  • Kennedy Capital Management's Atara Biotherapeutics position peaked at $503K in Q3 2020.
  • 148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Kennedy Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.